Clinical Trial Update: A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 study of AT-101 in combination with docetaxel for squamous cell carcinoma of the head and neck was terminated, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• AT-101 (gossypol acetic acid)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Phase 2 | Status: TERMINATED | Results posted: 2015-07-23